HOME >> MEDICINE >> NEWS
Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL
'"/>

Contact: Robert Sebbag/Beth Waters
33-60-817-2183
Cooney Waters Group, Inc.
25-Feb-2002


Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aventis Pasteur statement HVTN decision

(Date:4/28/2015)... 28, 2015 PFC Fitness Camp, the ... La Costa Resort and Spa partners with MD Revolution ... loss and overall health at home. Utilizing wearable fitness ... PFC RevUp ensures the healthy habits and results achieved ... life kick in and  clients are left to their own devices. , ...
(Date:4/28/2015)... Two leaders in patient safety from the ... Hospital Review’s list of 50 Experts Leading the Field ... , director of the Armstrong Institute for Patient ... patient safety and quality at Johns Hopkins Medicine, and ... medical affairs and chief patient safety officer at All ...
(Date:4/28/2015)... The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... for 3,822 of the pharmaceutical and 1,998 of the ...
(Date:4/28/2015)... Kansas City, Missouri (PRWEB) April 28, 2015 ... dedicated exclusively to healthcare executive search, announced today that ... Vice President & Chief Operating Officer search for ... Hawaii. . , Reporting to QHS President & ... Chief Operating Officer will have operating responsibility for the ...
(Date:4/28/2015)... A new survey from National Stroke Association ... of Americans fear brain damage the most. The results, ... shed light on the need for greater awareness of the ... By controlling modifiable risk factors, 80 percent of strokes ... brain attack ” that occurs when blood flow to the ...
Breaking Medicine News(10 mins):Health News:PFC Fitness Camp Launches Bullet-Proof Accountability Platform for Sustained Weight Loss At Home 2Health News:PFC Fitness Camp Launches Bullet-Proof Accountability Platform for Sustained Weight Loss At Home 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4Health News:The Queen’s Health Systems Retains MSA Executive Search to Recruit Executive Vice President & Chief Operating Officer 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 3
(Date:4/28/2015)... SAN ANTONIO , April 28, 2015 /PRNewswire/ ... that the U.S. Patent and Trademark Office has ... GenSpera,s intellectual property portfolio claiming numerous compositions for ... Prostate Specific Antigen (PSA).  GenSpera ... specific peptides with a powerful cytotoxin isolated from ...
(Date:4/28/2015)... 2015 /CNW/ - The group representing the living victims of ... a two-hour meeting with Health Canada officials in a ... Canada announced a $180 million support package for Thalidomide ... after the Health Canada announcement and five months after ... victims, the group representing Canada,s ...
(Date:4/28/2015)... April 28, 2015 Anteo Technologies is ... new tools developed with their patented Mix&Go™ Activation ... methods, helping to improve medical devices and in-vitro ... Increasingly complex multifactorial diagnosis of cancer and ... It is restricted to measure only a ...
Breaking Medicine Technology:GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen 2Thalidomide Victims Gravely Concerned by Health Canada's Silence 2Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 2Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 3
Cached News: